

# State Street SPDR S&P Biotech ETF (XBI)

InsiderStreet  
ETF FACTSHEET

AMEX · inception 2006-02-06 · beta 1.10 · avg volume 9,134,268 · holdings as of 2026-10-15 · prices through 2026-10-16 Built 2026-10-18

|                      |                        |                               |                              |                                     |                               |
|----------------------|------------------------|-------------------------------|------------------------------|-------------------------------------|-------------------------------|
| AUM<br><b>\$7.5B</b> | HOLDINGS<br><b>159</b> | TOP-10 WEIGHT<br><b>18.0%</b> | 1-YR RETURN<br><b>+33.2%</b> | MAX DRAWDOWN<br>5Y<br><b>-53.2%</b> | VOLATILITY 1Y<br><b>28.8%</b> |
|----------------------|------------------------|-------------------------------|------------------------------|-------------------------------------|-------------------------------|

## PERFORMANCE VS S&P 500 (SPY)



Rebased to 100 five years ago, weekly adjusted closes. Max drawdown is the largest peak-to-trough fall in that window (trough 2022-05-11). 3y and 5y returns are cumulative.

## TOP HOLDINGS

| #  | TICKER | NAME                        | WEIGHT |
|----|--------|-----------------------------|--------|
| 1  | MRNA   | MODERNA INC                 | 2.58%  |
| 2  | NTRA   | NATERA INC                  | 1.84%  |
| 3  | TWST   | TWIST BIOSCIENCE CORP       | 1.82%  |
| 4  | ABBV   | ABBVIE INC                  | 1.73%  |
| 5  | BIIB   | BIOGEN INC                  | 1.71%  |
| 6  | AMGN   | AMGEN INC                   | 1.68%  |
| 7  | HALO   | HALOZYME THERAPEUTICS INC   | 1.68%  |
| 8  | IOVA   | IOVANCE BIOTHERAPEUTICS INC | 1.67%  |
| 9  | UTHR   | UNITED THERAPEUTICS CORP    | 1.64%  |
| 10 | GILD   | GILEAD SCIENCES INC         | 1.63%  |

## EXPOSURE

| Sector             |       | Country |       |
|--------------------|-------|---------|-------|
| Healthcare         | 99.3% | US      | 95.3% |
| Financial Services | 0.6%  | CH      | 1.4%  |
| Unclassified       | 0.2%  | IE      | 1.4%  |

|              |             |      |
|--------------|-------------|------|
| GB           | <div></div> | 1.2% |
| NL           | <div></div> | 0.4% |
| Unclassified | <div></div> | 0.2% |

Weights of holdings joined to company profiles; bonds, cash and derivatives fall under Unclassified.

INSIDERSTREET SCORES OF THE HOLDINGS

| HOLDINGS-WEIGHTED SCORE | SCORE  | PERCENTILE VS ETFS | PORTFOLIO FUNDAMENTALS | VALUE  |
|-------------------------|--------|--------------------|------------------------|--------|
| Overall                 | 48/100 | 8                  | P/E                    | 57.0   |
| Quality                 | 55/100 | 3                  | P/B                    | 11.0   |
| Profitability           | 42/100 | 7                  | P/S                    | 8.3    |
| Balance sheet           | 58/100 | 29                 | Earnings yield         | 1.8%   |
| Earnings quality        | 51/100 | 2                  | FCF yield              | 3.4%   |
| Growth                  | 56/100 | 39                 | ROE                    | 5.3%   |
| Value                   | 38/100 | 3                  | Net margin             | 3.9%   |
| Momentum                | 62/100 | 4                  | Revenue growth (yoy)   | +34.7% |
| Risk (safety)           | 75/100 | 46                 | Dividend yield         | 0.12%  |
|                         |        |                    | Debt / equity          | 1.22   |

Scores are weighted by holding; 99% of the fund's weight is in companies we score. Percentile ranks the fund among ETFs with at least half their weight scored. A score describes the holdings, not the outlook for the fund.

MOST SIMILAR ETFS BY HOLDINGS OVERLAP

| ETF   | NAME                                           | OVERLAP | SHARED HOLDINGS | AUM      |
|-------|------------------------------------------------|---------|-----------------|----------|
| LABU  | Direxion Daily S&P Biotech Bull 3X Shares      | 99.9%   | 156             | \$1.1B   |
| TDNA  | T. Rowe Price Biotech ETF                      | 58.8%   | 69              | \$9.1M   |
| BIPIX | ProFunds Biotechnology UltraSector Fund Invest | 54.7%   | 108             | \$320.2M |
| BBP   | Virtus Biotech ETF                             | 48.1%   | 47              | \$40.8M  |
| IBB   | iShares Biotechnology ETF                      | 43.8%   | 122             | \$10.4B  |
| IBBQ  | Invesco Nasdaq Biotechnology ETF               | 43.3%   | 118             | \$79.9M  |

Overlap = sum over shared holdings of the smaller of the two weights.

**Method and disclosures.** Every figure is computed in code from InsiderStreet's production data (fund holdings filings and disclosures, exchange prices, company fundamentals). This factsheet contains no model-written text. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any person. Expense ratio is not shown: it is not in our data set. Past performance does not guarantee future results. © 2026 InsiderStreet.ai.